31 results about "Uvea" patented technology

A surgical technique wherein an indwelling shunt is placed in the eye of a patient having glaucoma. The shunt diverts aqueous humor from a deep scleral lake or directly from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. This decreases the intra-ocular pressure. The indwelling shunt maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the 25 mm Hg driving force of the protein colloidal osmotic pressure of the blood to maximize the flow.

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space. Alternatively, or in addition, the implant can elute a drug or therapeutic agent. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile package for use by the surgeon, doctor or operator.

The methods and apparatus disclosed herein can be used to treat glaucoma of the eye. The methods and apparatus can be configured to apply energy to the sclera, cornea, and / or other regions of the eye in order to shrink collagenous tissue near Schlemm's canal. Juxtacanalicular treatment of the sclera and / or cornea adjacent Schlemm's canal can be used to dilate Schlemm's canal, collector channels, and / or the Trabecular Meshwork. The methods and apparatus can be configured to apply energy to the sclera to generate scleral vacuoles in the sclera to improve uveoscleral outflow.

Ophthalmic adhesive preparations for percutaneous absorption to be used in treating diseases in the posterior parts of eye characterized by having a drug-containing layer which contains a drug to be delivered to the posterior parts of eye including the crystalline lens, the vitreous body, the uvea and the retina, together with a percutaneous sorbefacient comprising polyoxyethylene oleyl ether and / or isopropyl myristate uniformly dispersed in a base matrix.

The invention discloses a composition for treating eye diseases by double-target / multi-target small nucleic acid and applications of the composition. The composition comprises two small nucleic acid molecules and a medicinal carrier, target genes of the two small nucleic acid molecules are selected from two of VEGF (vascular endothelial growth factor) gene, VEGFR2 (vascular endothelial growth factor receptor2) gene and TGF-b1 (transforming growth factor-beta1) gene; or the composition comprises three small nucleic acid molecules and a medicinal carrier, and target genes of the three small nucleic acid molecules are respectively VEGF gene, VEGFR2 gene and TGF-b1 gene. The composition can be used for effectively treating eye diseases by virtue of ribonucleic acid interference (RNAi) mediated inhibitor gene expression and biochemical pathway, and can be prepared to form a medicament for treating eye diseases, including proliferatived diabetic retinophathy, diabetic macular edema, herpes simplex interstitial keratitis, age-related macular degeneration, uveitis and the like.

The invention relates to a traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation. The traditional Chinese medicine monomer combination comprises the following components in parts by weight: 1.5 to 6.0 parts of ligustrazine, 0.5 to 1.5 parts of catalpol, 1.5 to 6.0 parts of ferulic acid, and 3.0 to 15 parts of paeoniflorin. According to the traditional Chinese medicine monomer combination, the conventional processing method is adopted and used for preparing injection, oral liquid, capsules, troches and preparations of other forms based on the traditional Chinese medicine monomer. The traditional Chinese medicine monomer combination is mainly used for resisting oxidization and protecting free radicals, can prevent and delay the deformation and development of cataract and improve the eyeground blood circulation, also can treat uvea and retina vascular diseases and eye malnutritional lesion, nourish optic nerve and recover visual functions from glaucoma, traumatic optic nerve diseases and visual pathway diseases.

Methods and kits for monitoring or providing a prognosis for a subject having uveal melanoma are described. The methods include obtaining a biological sample from the subject, determining the expression level of one or more uveal melanoma-associated miRs and / or miR biogenesis factors in the biological sample, and characterizing the subject as high risk if one or more uveal melanoma-associated miRs and / or miR biogenesis factors are differentially expressed as compared with a corresponding control.

The invention discloses a preparation for treating, preventing and / or slowing down uveal melanoma, the preparation comprises oncolytic herpes simplex virus type 1 capable of expressing cytosine deaminase genes and 5-fluorocytosine, and the oncolytic herpes simplex virus type 1 and the 5-fluorocytosine are combined to significantly reduce the volume of the uveal melanoma and improve the lifetime ofa subject. The invention further discloses a marker for evaluating the treatment effect of uveal melanoma through the preparation, and the marker is selected from markers capable of representing theepithelial-mesenchymal transition degree and mainly comprises IL-6, DPD, TWIST1, ZEB1, CD44 and CDH1.

The invention provides application of a small molecule in preparation of a mutant type uveal melanoma drug. The small molecule is elesclomol, and the mutant type uveal melanoma comprises GNAQ or GNA11 mutant type uveal melanoma. The small molecule elesclomol aims at the GNAQ / GNA11 mutant type uveal melanoma, can effectively kill mutant type UM cells, effectively inhibit proliferation of the mutant type UM cells, block the cell cycle to the G1 stage, can well inhibit proliferation and transfer of the GNAQ / GNA11 mutant type UM cells in vivo, and has a poor killing effect on wild type UM cells, thereby showing a specific killing effect on the GNAQ / GNA11 mutant type UM cells. The drug effect of the elesclomol is increased with the increase of the concentration, and the molecular structural formula of the elesclomol is shown as the formula (I) seeing the description.

The invention relates to the field of anticancer medicines and particularly discloses an application of a CTCF snare protein in preparation of an anti-uveal melanoma medicine. The CTCF snare protein is an artificially expressed recombinant protein, wherein N-terminal and C-terminal functional zones of a wild-type CTCF are removed, while a zinc finger structure ZF is remained and DNA methylase Sss1 is added. A researching result proves that by transferring the CTCF snare in an UM cell, growth and metastasis of the uveal melanoma can be effectively inhibited. The CTCF snare protein provides a new target point and a therapy medicine for clinical treatment of the uveal melanoma, improves therapy validity, reduces rate of eyeball removal, and improves visional prognosis of patients.

The present invention provides an in vitro method for detecting tumor growth and diagnosing or prognosticating the risk of metastasis in a human subject that has been diagnosed with uveal melanoma, wherein the method comprises using, as an indicator, the levels of PMEL / ME20-S / gp 100 positive exosomes, obtained from a biological sample isolated from the human subject selected from the list consisting of blood, or serum, of at least melanocyte protein PMEL / ME20-S / gp 100, and obtaining a result of the method by comparing the levels of at least said protein with a reference value or with the levels of a control, wherein an increase of melanocyte protein PMEL / ME20-S / gp 100 is indicative of a risk of the patient having or suffering from metastasis.

The invention discloses a uveal melanoma prognosis risk scoring model and application thereof, and particularly discovers that SLC12A3, SLC12A9, MIR140 and HCP5 are significantly related to the prognosis of a patient with uveal melanoma, the uveal melanoma prognosis risk scoring model is constructed for the first time according to the four genes, and then a risk score is obtained. The clinical result of uveal melanoma can be predicted through risk scoring, and the method has a good clinical application prospect.

Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

The invention provides a novel uveal melanoma metastasis risk prediction kit, and belongs to the field of disease molecular diagnosis kits. According to the kit, a relationship between a p.E725K mutation site of an EZH2 gene and uveal melanoma metastasis is elaborated; and the novel kit is provided, wherein the kit realizes effective prediction of the uveal melanoma metastasis risk by virtue of detection of the p.E725K mutation site of the EZH2 gene, and the kit has a good application prospect.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

The invention discloses an application of SLC12A3 and / or SLC12A9 as an index for treatment and prognosis detection of uveal melanoma. The invention further discloses a calculation model for predicting uveal melanoma prognosis and a medicine for preventing or treating uveal melanoma. The invention provides a new method for prognosis monitoring and treatment of uveal melanoma patients.

The invention discloses an ophthalmic pharmaceutical composition containing sirolimus, which includes sirolimus, astragalus polysaccharide, sodium tanshinone IIA sulfonate and rehmannia glutinosa extract, and is prepared according to a common method. The preparation for external use on the eye is suitable for treating ocular immune diseases such as uveitis and rejection after corneal transplantation. Compared with the common sirolimus ophthalmic preparation, it has better drug efficacy and less side effects.

Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and / or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.

The invention relates to a traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation. The traditional Chinese medicine monomer combination comprises the following components in parts by weight: 1.5 to 6.0 parts of ligustrazine, 0.5 to 1.5 parts of catalpol, 1.5 to 6.0 parts of ferulic acid, and 3.0 to 15 parts of paeoniflorin. According to the traditional Chinese medicine monomer combination, the conventional processing method is adopted and used for preparing injection, oral liquid, capsules, troches and preparations of other forms based on the traditional Chinese medicine monomer. The traditional Chinese medicine monomer combination is mainly used for resisting oxidization and protecting free radicals, can prevent and delay the deformation and development of cataract and improve the eyeground blood circulation, also can treat uvea and retina vascular diseases and eye malnutritional lesion, nourish optic nerve and recover visual functions from glaucoma, traumatic optic nerve diseases and visual pathway diseases.

Provided is a composition comprising a mutant Q209L-GNAQ DNA vaccine encoding, in a N-terminal to C-terminal direction, a fusion protein comprising VP22 or an HLA-binding sequence thereof, a mutant GNAQ sequence comprising a Q209L mutation, and a PADRE epitope. Also provided are methods of treatment and methods of vaccination comprising administering to a patient the composition. Also provided is a method of generating mutant GNAQ-specific T cells comprising priming T cells with ex vivo cultured dendritic cells transduced or electroplated with the composition.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

The invention relates to a method for generating a hiPSC-RPE cell sheet by combining with biological matrigel, which comprises the following steps: step S1, preparing decellularized matrigel from pretreated pig eye grape membrane; step S2, maintaining the culture of the hiPSCs; step S3, culturing the hiPSC-RPE suspension ball; step S4, carrying out multiplication culture on the hiPSC-RPE cells; step S5, generating a hiPSC-RPE cell membrane sheet; wherein in the step S5, a Uvea-Gel coated culture dish with the concentration of 1% is placed at the temperature of 37 DEG C for about 30 min, and after Uvea-Gel is solidified, a layer of thin film sample area, namely a BM film, is formed and is used for simulating a natural BM microenvironment. According to the method, the decellularized matrix hydrogel separated and prepared from pig choroidal tissue is optimized, the hiPSC-RPE cells are obtained in combination with an established hiPSC-induced 3D retinal differentiation system, a method for generating the RPE sheet by simulating a Bruch membrane (BM) microenvironment is established, and a safe and effective biological material is provided for culturing GMP-level stem cells.

Provided herein are methods of treating ocular cancer such as uveal melanoma, orbital lymphoma, retinoblastoma, and medulloepithelioma using antibodies and bispecific antigen-binding molecules that bind MET or antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different epitopes of the extracellular domain of human MET. The ADCs comprise the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety. The antibodies and bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. A subject having ocular cancer, for example, an uveal melanoma expressing c-Met, can be treated by administering to the subject an antibody, a bispecific antigen-binding molecule, or an ADC thereof.